Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1Advanced Solid Tumors 1

Interventions

Injections 8pembrolizumab 4Pemetrexed 4Carboplatin 4Oxaliplatin 3Leucovorin 3Fluorouracil 3trifluridine tipiracil drug combination 2sotorasib 2fludarabine 2Paclitaxel 2Drug Therapy 2Docetaxel 2Bevacizumab 2zimberelimab 1trametinib 1toripalimab 1tislelizumab 1sacituzumab govitecan 1netrin-1 inhibitor NP137 1cemiplimab 1WW Domain-Containing Oxidoreductase 1SYS6006 COVID-19 vaccine 1Panitumumab 1Irinotecan 1Immune Checkpoint Inhibitors 1Etoposide 1Cyclophosphamide 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × WW Domain-Containing Oxidoreductase × 90 days × Clear all
NCT06726369 2026-05-07

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 1 Recruiting
90 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡